TickerTalks
Browse all tickers →
TickerTalks›$CATX
CACATX

Perspective Therapeutics, Inc.

$CATX·$225M·Medical - Devices·Healthcare
$2.87+1.8%YTD+2.5%1Y-31.6%
Mentions · last 7 days
2026-07-21: 2 posts2026-07-22: 1 posts2026-07-23: 0 posts2026-07-24: 0 posts2026-07-25: 2 posts2026-07-26: 0 posts2026-07-27: 0 posts5
Price updated 9m ago·X counts updated 22h ago
CACATX
$CATXPerspective Therapeutics, Inc.
$2.87+1.77%5 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $CATX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-07-28

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Radiopharmaceutical oncology name with ESMO 2026 oral presentation accepted for VMT-alpha-NET data — pipeline optionality with a real near-term event.

Perspective Therapeutics develops radiopharmaceutical products for cancer including the VMT-alpha-NET candidate that just had ESMO 2026 oral-presentation data acceptance on July 17 — a real clinical-catalyst setup in a therapeutic area investors have been rewarding.

  • Q1 revenue of $76K with an EPS of -$25.28 that reflects accounting noise — the underlying operational trajectory is on the clinical pipeline, not the P&L.
  • July 17 ESMO Congress 2026 acceptance for VMT-alpha-NET oral presentation — a real high-visibility data catalyst that could re-rate the story.
  • June 3 first brain tumor patient dosed in expanded radiopharmaceutical trial plus July 8 CSO appointment — real clinical and organisational progress.

August 12 earnings will bring updated cash runway plus any ESMO-related teaser commentary — the ESMO oral presentation itself is the specific catalyst that could re-rate the story, while continued cash burn without pipeline milestones keeps it coiled. Risk: single-asset radiopharmaceutical stories have historically been binary on clinical readouts, and even positive data has to overcome the crowded competitive landscape in neuroendocrine tumors.

Differs from X sentimentNo X chatter in the bundle for CATX to compare against the catalyst-play-coiling read — flagging as no-crowd-read.

What to watch: The August 12 earnings for cash runway detail and any ESMO 2026 teaser commentary, plus the actual VMT-alpha-NET oral presentation data content at the congress.

Read the AI verdict + X sentiment for $CATX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $CATX.

Medical - Devices · Healthcare

No material change from last week — ISRG's da Vinci 5 procedure growth (+23%) confirms surgical robotics has transitioned from premium to standard-of-care in major procedures.

Industry benchmark

18-name peer basket
-10.0%YTD
-2.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-0.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-31.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-194%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-47.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
363.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-41.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-490%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 11, 2026$-0.25$-0.29+13.8%
Q4 2025Mar 16, 2026$-0.51$-0.37-37.8%
Q3 2025Nov 10, 2025$-0.35$-0.33-6.1%
Q2 2025Aug 13, 2025$-0.30$-0.300.0%
Next earningsWed, Aug 12·consensus EPS $-0.27

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$76K-77.8%-1382%-37212%$-25.28$-38.3M
Q4 FY25$43K-81.6%-2251%-92633%$-0.51$-29.7M
Q3 FY25$209K-43.4%-271%-13331%$-0.35$-18.3M
Q2 FY25$290K-44.9%-153%-8289%$-0.30$-21.0M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$374K$65K – $813K-$1.09-$1.26 – -$0.8710
FY27$449K$346K – $595K-$1.10-$1.43 – -$0.777
FY28$15.1M$11.6M – $20.0M-$1.02-$1.29 – -$0.709
FY29$249.4M$192.3M – $330.5M-$0.21-$0.30 – -$0.154
FY30$348.4M$268.6M – $461.7M$0.72$0.51 – $1.034

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.20%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-14.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-21.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 50.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.755-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 8 other (8 awards) in window

See when $CATX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteMay 278-K — Item 5.07: Shareholder vote
8-KMaterial agreementFeb 38-K — Item 1.01: Material agreement · Item 8.01: Other event
424B5Prospectus supplement (offering)Feb 3424B5
+ 22 other (9 13Gs · 5 routine 8-Ks · 4 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026globenewswire.com·11d agoIs Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?zacks.com·12d agoPerspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K.globenewswire.com·21d agoPerspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trialproactiveinvestors.com·55d agoPerspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trialproactiveinvestors.com·55d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ISRG$MDT$BIO$TMDX$BSX$EW$ABT$NVCR
Voices on X · last 7 days

No standout posts about $CATX on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport